OSR HOLDINGS INC (OSRH) Stock Fundamental Analysis

USA Nasdaq NASDAQ:OSRH • US68840D1028

0.5789 USD
+0.01 (+1.03%)
At close: Feb 4, 2026
0.55 USD
-0.03 (-4.99%)
Pre-Market: 2/5/2026, 9:09:20 AM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to OSRH. OSRH was compared to 524 industry peers in the Biotechnology industry. Both the profitability and financial health of OSRH have multiple concerns. OSRH does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • In the past year OSRH has reported negative net income.
  • In the past year OSRH has reported a negative cash flow from operations.
  • In the past 5 years OSRH reported 4 times negative net income.
  • OSRH had a negative operating cash flow in each of the past 5 years.
OSRH Yearly Net Income VS EBIT VS OCF VS FCFOSRH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 -1M -2M -3M

1.2 Ratios

  • OSRH has a better Return On Assets (-8.58%) than 84.73% of its industry peers.
  • Looking at the Return On Equity, with a value of -18.56%, OSRH belongs to the top of the industry, outperforming 83.97% of the companies in the same industry.
Industry RankSector Rank
ROA -8.58%
ROE -18.56%
ROIC N/A
ROA(3y)-1.18%
ROA(5y)-1.96%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OSRH Yearly ROA, ROE, ROICOSRH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 20 40 60 80

1.3 Margins

  • OSRH does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OSRH Yearly Profit, Operating, Gross MarginsOSRH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

1

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, OSRH has less shares outstanding
  • Compared to 1 year ago, OSRH has a worse debt to assets ratio.
OSRH Yearly Shares OutstandingOSRH Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2M 4M 6M 8M
OSRH Yearly Total Debt VS Total AssetsOSRH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • Based on the Altman-Z score of -0.49, we must say that OSRH is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -0.49, OSRH perfoms like the industry average, outperforming 58.59% of the companies in the same industry.
  • A Debt/Equity ratio of 0.05 indicates that OSRH is not too dependend on debt financing.
  • OSRH has a Debt to Equity ratio (0.05) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z -0.49
ROIC/WACCN/A
WACCN/A
OSRH Yearly LT Debt VS Equity VS FCFOSRH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

  • OSRH has a Current Ratio of 0.21. This is a bad value and indicates that OSRH is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 0.21, OSRH is doing worse than 92.56% of the companies in the same industry.
  • A Quick Ratio of 0.20 indicates that OSRH may have some problems paying its short term obligations.
  • OSRH has a Quick ratio of 0.20. This is amonst the worse of the industry: OSRH underperforms 92.75% of its industry peers.
Industry RankSector Rank
Current Ratio 0.21
Quick Ratio 0.2
OSRH Yearly Current Assets VS Current LiabilitesOSRH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 1M 2M 3M

1

3. Growth

3.1 Past

  • OSRH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -253.93%.
  • OSRH shows a strong growth in Revenue. In the last year, the Revenue has grown by 186.30%.
EPS 1Y (TTM)-253.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-74.83%
Revenue 1Y (TTM)186.3%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • OSRH is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -43.77% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-83.94%
EPS Next 2Y-43.77%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
OSRH Yearly Revenue VS EstimatesOSRH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 1M 2M 3M
OSRH Yearly EPS VS EstimatesOSRH Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 -0.2 -0.4 -0.6 -0.8 -1

0

4. Valuation

4.1 Price/Earnings Ratio

  • OSRH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year OSRH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OSRH Price Earnings VS Forward Price EarningsOSRH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OSRH Per share dataOSRH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

  • OSRH's earnings are expected to decrease with -43.77% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-43.77%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

  • OSRH does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

OSR HOLDINGS INC

NASDAQ:OSRH (2/4/2026, 8:00:03 PM)

Premarket: 0.55 -0.03 (-4.99%)

0.5789

+0.01 (+1.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12
Earnings (Next)04-17
Inst Owners0.88%
Inst Owner Change5.02%
Ins Owners0.08%
Ins Owner Change0%
Market Cap14.86M
Revenue(TTM)2.52M
Net Income(TTM)-15.21M
Analysts82.86
Price Target10.2 (1661.96%)
Short Float %8.01%
Short Ratio0.19
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.89
P/FCF N/A
P/OCF N/A
P/B 0.18
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.73
EYN/A
EPS(NY)-1.11
Fwd EYN/A
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)-0.15
OCFYN/A
SpS0.1
BVpS3.19
TBVpS-3.57
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -8.58%
ROE -18.56%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-1.18%
ROA(5y)-1.96%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.21
Quick Ratio 0.2
Altman-Z -0.49
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-253.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-74.83%
EPS Next Y-83.94%
EPS Next 2Y-43.77%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)186.3%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-183.2%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-615.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-597.38%
OCF growth 3YN/A
OCF growth 5YN/A

OSR HOLDINGS INC / OSRH FAQ

Can you provide the ChartMill fundamental rating for OSR HOLDINGS INC?

ChartMill assigns a fundamental rating of 1 / 10 to OSRH.


What is the valuation status for OSRH stock?

ChartMill assigns a valuation rating of 0 / 10 to OSR HOLDINGS INC (OSRH). This can be considered as Overvalued.


Can you provide the profitability details for OSR HOLDINGS INC?

OSR HOLDINGS INC (OSRH) has a profitability rating of 2 / 10.


How financially healthy is OSR HOLDINGS INC?

The financial health rating of OSR HOLDINGS INC (OSRH) is 1 / 10.


Can you provide the expected EPS growth for OSRH stock?

The Earnings per Share (EPS) of OSR HOLDINGS INC (OSRH) is expected to decline by -83.94% in the next year.